Surface Oncology, Inc.
SURFDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)
Dry Eye Disease
SURF-201
Post-surgical Ocular Inflammation
0.02% Betamethasone Sodium Phosphate
Dry Eye Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate) | Phase 2 | Dry Eye Disease | - | - |
SURF-201 | Phase 2 | Post-surgical Ocular Inflammation | - | - |
0.02% Betamethasone Sodium Phosphate | Phase 2 | Dry Eye Disease | - | - |
Frequently asked questions
What is in Surface Oncology, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Surface Oncology, Inc.'s (SURF) pipeline across Phase 2. Its lead program is SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Surface Oncology, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Surface Oncology, Inc. (SURF) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SURF biotech catalysts?→
Add SURF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Surface Oncology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.